Lu­pus drug mar­ket grow­ing as physi­cians adopt new­er op­tions — and look for more, re­search finds

With three rel­a­tive­ly new drugs, plus a busy pipeline in both sys­temic lu­pus ery­the­mato­sus (SLE) and lu­pus nephri­tis (LN), the lu­pus mar­ket has been tak­ing off. The LN are­na is es­pe­cial­ly busy now with two com­peti­tors gain­ing steam, but SLE is al­so on physi­cians’ minds with the po­ten­tial for CAR-T cell ther­a­py treat­ment on the hori­zon, ac­cord­ing to re­search from Spher­ix Glob­al In­sights.

While lu­pus CAR-T stud­ies have been around for a few years, the po­ten­tial for now al­most a dozen in de­vel­op­ment, most­ly in Phase I or Phase II stud­ies for both SLE and LN, is gen­er­at­ing some ex­cite­ment among physi­cians, said Spher­ix se­nior in­sights an­a­lyst Sawyer May.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER